Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal unit in cholestasis during pregnancy.
Maternal cholestasis causes oxidative damage to the placental-fetal unit that may challenge the outcome of pregnancy. This has been associated with the accumulation of biliary compounds able to induce oxidative stress. However, other cholephilic compounds such as ursodeoxycholic acid (UDCA) and bilirubin have direct anti-oxidant properties. In the present study we investigated whether these compounds exert a protective effect on cholestasis-induced oxidative stress in placenta as compared to maternal and fetal livers, and whether this is due in part to the activation of anti-oxidant mechanisms involving vitamin C uptake and biliverdin/bilirubin recycling. In human placenta (JAr) and liver (HepG2) cells, deoxycholic acid (DCA) similar rates of free radical generation. In JAr (not HepG2), the mitochondrial membrane potential and cell viability were impaired by low DCA concentrations; this was partly prevented by bilirubin and UDCA. In HepG2, taurocholic acid (TCA) and UDCA up-regulated biliverdin-IX alpha reductase (BVR alpha) and the vitamin C transporter SVCT2 (not SVCT1), whereas bilirubin up-regulated both SVCT1 and SVCT2. In JAr, TCA and UDCA up-regulated BVR alpha, SVCT1 and SVCT2, whereas bilirubin up-regulated only SVCT2. A differential response to these compounds of nuclear receptor expression (SXR, CAR, FXR and SHP) was found in both cell types. When cholestasis was induced in pregnant rats, BVR alpha, SVCT1 and SVCT2 expression in maternal and fetal livers was stimulated, and this was further enhanced by UDCA treatment. In placenta, only BVR alpha was up-regulated. In conclusion, bilirubin accumulation and UDCA administration may directly and indirectly protect the placental-fetal unit from maternal cholestasis-induced oxidative stress.
Perez
Maria J
MJ
Research Unit, University Hospital, Salamanca, Spain.
Castaño
Beatriz
B
Jimenez
Silvia
S
Serrano
Maria A
MA
Gonzalez-Buitrago
Jose M
JM
Marin
Jose J G
JJ
D000818:Animals; D000975:Antioxidants / Q000633:toxicity*; D001205:Ascorbic Acid / Q000378:metabolism*; D045744:Cell Line, Tumor; D002779:Cholestasis / Q000139:chemically induced / Q000201:enzymology / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008431:Maternal-Fetal Exchange / Q000187:drug effects / Q000502:physiology*; D029363:Organic Anion Transporters, Sodium-Dependent / Q000502:physiology; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D044925:Oxidoreductases Acting on CH-CH Group Donors / Q000502:physiology*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced / Q000201:enzymology / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism / Q000633:toxicity*; D014580:Ursodeoxycholic Acid / Q000633:toxicity
D000975:Antioxidants; D029363:Organic Anion Transporters, Sodium-Dependent; D017382:Reactive Oxygen Species; D014580:Ursodeoxycholic Acid; D044925:Oxidoreductases Acting on CH-CH Group Donors; C019789:biliverdin reductase; D001205:Ascorbic Acid